Encorafenib + Cetuximab + FOLFIRI
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600E
Conditions
BRAF V600E, Metastatic Colorectal Cancer
Trial Timeline
Sep 14, 2021 → Dec 7, 2024
NCT ID
NCT05004350About Encorafenib + Cetuximab + FOLFIRI
Encorafenib + Cetuximab + FOLFIRI is a phase 2 stage product being developed by Merck for BRAF V600E. The current trial status is completed. This product is registered under clinical trial identifier NCT05004350. Target conditions include BRAF V600E, Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05004350 | Phase 2 | Completed |
Competing Products
13 competing products in BRAF V600E
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 52 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 23 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 41 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 25 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |